CY1106032T1 - Υποκατασταθεισες πυραζολες - Google Patents

Υποκατασταθεισες πυραζολες

Info

Publication number
CY1106032T1
CY1106032T1 CY20071100223T CY071100223T CY1106032T1 CY 1106032 T1 CY1106032 T1 CY 1106032T1 CY 20071100223 T CY20071100223 T CY 20071100223T CY 071100223 T CY071100223 T CY 071100223T CY 1106032 T1 CY1106032 T1 CY 1106032T1
Authority
CY
Cyprus
Prior art keywords
substituted pyrazoles
methods
pyrazoles
substituted
cathepsin
Prior art date
Application number
CY20071100223T
Other languages
English (en)
Inventor
J. Guy Breitenbucher
Hui Cai
James P. Edwards
Cheryl A. Grice
Darin J. Gustin
Haripada Khatuya
Steven P. Meduna
Barbara A. Pio
Kevin L. Tays
Jianmei Wei
Mary Pat Beavers
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of CY1106032T1 publication Critical patent/CY1106032T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Περιγράφονται υττοκατασταθείσες πυραζόλες, μέθοδοι παραγωγής τους, συνθέσεις που τις περιέχουν και μέθοδοι χρήσεως τους για την αγωγή, για παράδειγμα, αυτοάνοσων νόσων στις οποίες μεσολαβεί η καθεψίνη S.
CY20071100223T 2000-08-14 2007-02-20 Υποκατασταθεισες πυραζολες CY1106032T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22513800P 2000-08-14 2000-08-14
US09/928,122 US7309703B2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles
PCT/US2001/025289 WO2002014314A2 (en) 2000-08-14 2001-08-10 Substituted pyrazoles

Publications (1)

Publication Number Publication Date
CY1106032T1 true CY1106032T1 (el) 2011-04-06

Family

ID=26919335

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100223T CY1106032T1 (el) 2000-08-14 2007-02-20 Υποκατασταθεισες πυραζολες

Country Status (17)

Country Link
US (9) US7309703B2 (el)
EP (1) EP1309591B1 (el)
JP (1) JP5140225B2 (el)
CN (1) CN1329392C (el)
AR (1) AR035714A1 (el)
AT (1) ATE352552T1 (el)
AU (2) AU2001281255B2 (el)
CA (1) CA2419540A1 (el)
CY (1) CY1106032T1 (el)
DE (1) DE60126286T2 (el)
DK (1) DK1309591T3 (el)
ES (1) ES2281434T3 (el)
HK (1) HK1052509B (el)
MX (1) MXPA03001421A (el)
NZ (1) NZ524193A (el)
PT (1) PT1309591E (el)
WO (1) WO2002014314A2 (el)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1329392C (zh) * 2000-08-14 2007-08-01 奥索-麦克尼尔药品公司 取代的吡唑
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
CA2433520A1 (en) * 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
JP4723242B2 (ja) * 2002-06-12 2011-07-13 ケモセントリックス インコーポレーティッド 炎症および免疫障害治療用ccr1アンタゴニストとして使用するための1−アリール−4−置換ピペラジン誘導体
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
GB0220214D0 (en) * 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
RU2478378C2 (ru) 2002-09-24 2013-04-10 Новартис Аг Органические соединения
US7384970B2 (en) 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7173051B2 (en) 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
SG146683A1 (en) 2003-09-17 2008-10-30 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
WO2005030148A2 (en) * 2003-09-25 2005-04-07 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
BRPI0514147A (pt) * 2004-08-12 2008-05-27 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
EP2078376B1 (en) * 2007-06-26 2010-12-29 Media Patents, S. L. Router for managing multicast groups
US20100046516A1 (en) * 2007-06-26 2010-02-25 Media Patents, S.L. Methods and Devices for Managing Multicast Traffic
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
WO2009102937A1 (en) * 2008-02-14 2009-08-20 Sunesis Pharmaceuticals, Inc. Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
US8829011B2 (en) 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
CA2758484A1 (en) 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP5530514B2 (ja) 2009-06-11 2014-06-25 アッヴィ・バハマズ・リミテッド Hcv感染を治療するための抗ウィルス化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
KR20170118706A (ko) 2014-12-30 2017-10-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염 감염을 치료하는 유도체 및 그 방법
ES2822979T3 (es) 2015-11-20 2021-05-05 Lundbeck La Jolla Research Center Inc Derivados de pirazol, procesos para su preparación, y sus usos
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10323038B2 (en) 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
WO2018005883A1 (en) 2016-06-29 2018-01-04 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis b infections
CN109843892B (zh) 2016-06-29 2022-01-25 诺维拉治疗公司 噁二氮杂卓酮衍生物及其在治疗乙型肝炎感染中的用途
CN116473965A (zh) * 2017-05-23 2023-07-25 H.隆德贝克有限公司 吡唑magl抑制剂
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
EP3884948A1 (en) * 2020-03-26 2021-09-29 Ecole Polytechnique Fédérale de Lausanne (EPFL) Cathepsin inhibitors and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914340A (en) * 1970-06-02 1975-10-21 Gen Tire & Rubber Co Block copolymerization with azoamidino compounds as initiator
JPS5720663B2 (el) * 1973-06-11 1982-04-30
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5640714B2 (el) 1974-03-04 1981-09-22
JPS5944312B2 (ja) * 1974-11-22 1984-10-29 中外製薬株式会社 インダゾ−ル誘導体の製法
JPS5936627B2 (ja) * 1975-07-25 1984-09-05 中外製薬株式会社 インダゾ−ル誘導体の製法
US4523928A (en) * 1980-04-28 1985-06-18 Battelle Development Corporation Gasohol production from thermochemical conversion of biomass to ethanol
US4401823A (en) * 1981-05-18 1983-08-30 Uop Inc. Hydrogenolysis of polyhydroxylated compounds
US4364745A (en) * 1981-06-26 1982-12-21 Standard Oil Company (Indiana) Plant hydrocarbon recovery process
DE3132915A1 (de) * 1981-08-20 1983-03-03 Kali-Chemie Pharma Gmbh, 3000 Hannover 1,5-diphenylpyrazolin-3-on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US4925540A (en) * 1988-10-04 1990-05-15 Delphi Research Inc. Method for treating organic waste material and an oxidation catalyst/cocatalyst composition useful therefor
FR2642759B1 (fr) 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
US5177169A (en) * 1989-04-03 1993-01-05 Colorado State University Research Foundation Method for recovering and using lignin in adhesive resins
FR2673628B1 (fr) 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5186722A (en) * 1991-06-25 1993-02-16 Cantrell Research, Incorporated Hydrocarbon-based fuels from biomass
JP2818061B2 (ja) * 1991-12-10 1998-10-30 三菱電機株式会社 放電加工装置
US5264576A (en) 1992-10-22 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Pyrazolo[4,3-c]pyridines which are intermediates
EP0635506A4 (en) 1993-02-04 1995-04-12 Meiji Seika Co CONNECTION WITH ANTIPSYCHOTIC EFFECT.
FR2712808B1 (fr) 1993-11-25 1996-02-16 Esteve Labor Dr Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5516960A (en) * 1994-08-02 1996-05-14 Board Of Regents, The University Of Texas System Process for producing hydrocarbon fuels
JPH11503417A (ja) 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション 可逆的プロテアーゼインヒビター
US5776718A (en) 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
AU5966196A (en) 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
FR2742052B1 (fr) 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
DE19602505A1 (de) 1996-01-25 1997-07-31 Merck Patent Gmbh 1-(Pyrazol-4-Indol-3-yl)-Piperidine
DE69726426T3 (de) 1996-04-22 2009-09-10 Massachusetts Institute Of Technology, Cambridge Unterdrückung von immunantwort durch hemmung von cathepsin s
IL120561A0 (en) 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
US5830850A (en) 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
GB9626643D0 (en) * 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
WO1998056785A1 (fr) 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyrazole
FR2767827A1 (fr) 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2306313C (en) 1997-11-05 2010-03-09 Novartis Ag Dipeptide nitriles
GB9806287D0 (en) 1998-03-24 1998-05-20 Synphar Lab Inc Monobactam enzyme inhibitors
WO1999058153A1 (en) 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンl及びカテプシンsの阻害剤としてのジ−及びトリペプチドニトリル誘導体
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
ATE326454T1 (de) 1999-07-30 2006-06-15 Boehringer Ingelheim Pharma Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
WO2001019808A1 (en) 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
KR20020062312A (ko) 1999-12-03 2002-07-25 오노 야꾸힝 고교 가부시키가이샤 1,3,4-옥사디아졸린 유도체 및 이들을 유효 성분으로하는 약제
US6214813B1 (en) 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
JP5049447B2 (ja) * 2000-08-14 2012-10-17 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
CN1329392C (zh) * 2000-08-14 2007-08-01 奥索-麦克尼尔药品公司 取代的吡唑
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1184443A1 (en) * 2000-09-04 2002-03-06 Biofuel B.V. Process for the production of liquid fuels from biomass
WO2002020012A2 (en) * 2000-09-06 2002-03-14 Ortho Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles

Also Published As

Publication number Publication date
US7429591B2 (en) 2008-09-30
US20070004747A1 (en) 2007-01-04
US7417046B2 (en) 2008-08-26
CN1329392C (zh) 2007-08-01
EP1309591B1 (en) 2007-01-24
ES2281434T3 (es) 2007-10-01
US20070010530A1 (en) 2007-01-11
NZ524193A (en) 2004-12-24
HK1052509B (zh) 2007-09-07
EP1309591A2 (en) 2003-05-14
ATE352552T1 (de) 2007-02-15
US20070004755A1 (en) 2007-01-04
PT1309591E (pt) 2007-04-30
US20070004754A1 (en) 2007-01-04
US7772236B2 (en) 2010-08-10
HK1052509A1 (en) 2003-09-19
MXPA03001421A (es) 2004-01-26
CA2419540A1 (en) 2002-02-21
DK1309591T3 (da) 2007-03-26
US7589202B2 (en) 2009-09-15
US7452890B2 (en) 2008-11-18
JP5140225B2 (ja) 2013-02-06
US7388011B2 (en) 2008-06-17
DE60126286T2 (de) 2007-11-15
JP2004512272A (ja) 2004-04-22
DE60126286D1 (de) 2007-03-15
US20070004738A1 (en) 2007-01-04
US20080293732A1 (en) 2008-11-27
WO2002014314A2 (en) 2002-02-21
WO2002014314A3 (en) 2002-06-06
AU2001281255B2 (en) 2006-07-20
US20070021437A1 (en) 2007-01-25
AU8125501A (en) 2002-02-25
US7393850B2 (en) 2008-07-01
CN1468239A (zh) 2004-01-14
US20020040020A1 (en) 2002-04-04
US20080300255A1 (en) 2008-12-04
US7309703B2 (en) 2007-12-18
AR035714A1 (es) 2004-07-07

Similar Documents

Publication Publication Date Title
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
DK1309593T3 (da) Substituerede pyrazoler
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DK1309592T3 (da) Substituerede pyrazoler
DE60228103D1 (de) Chemische verbindungen
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE312096T1 (de) Neue verbindungen
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
DE60228295D1 (de) Chemische verbindungen
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης
CO5150221A1 (es) Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
CY1106196T1 (el) Χρηση υποκατασταθεισων πυραζολων για την παραγωγη ενος φαρμακου για την αγωγη αλλepγιων